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1. Introduction
Parkinson’s disease (PD) is the second most common neurodegenerative disease that affects
more than 5 million people, accounting to 1-2 % of the population worldwide. It is character‐
ized by the loss of dopaminergic neurons in the substantia nigra associated with the formation
of fibrillar aggregates that are composed of α-synuclein and other proteins [1]. PD is clinical
characterized by four major symptoms; tremor, bradykinesia, rigidity and postural instability.
Initially PD was considered sporadic, however genetic studies in patients families revealed
mutations that are segregating with PD. Nowadays, in addition to environmental factors,
mutations within 6 loci (SNCA, LRRK2, PRKN, DJ1, PINK1 and ATP13A2) have been clearly
demonstrated to be causative to familial PD [2-4]. Among them, SNCA and LRRK2 mutations
cause autosomal dominant forms of PD [5]. Human leucine-rich-repeat kinase 2 (LRRK2) has
been found to be thus far the most frequent cause of late-onset PD [6, 7]. The identification of
missense mutations in LRRK2 has redefined the role of genetic variation in PD susceptibility.
The mutations are found in 5-6 % of patients with familial PD, and also have been implicated
with sporadic PD [8]. LRRK2 mutations initiate a penetrant phenotype with complete clinical
and neurochemical overlap with idiopathic PD (IPD). Penetrance is age-related, around 75 %
mutation carriers showed PD symptoms at the age of 80 [9, 10]. Tremor is more commonly
observed in LRRK2 mediated PD compared to IPD [11]. Although dementia and cognitive
defects are not frequently present in patients with mutations in LRRK2, LRRK2 does associate
with Lewy bodies in IPD and dementia [12-14].
LRRK2 belongs to the Roco family of proteins, which constitute a novel family of Ras-like G-
proteins that have an unique domain architecture [15]. LRRK2 is a large and complex protein
with multiple domains; Armadillo repeats (ARM), Ankyrin repeats (ANK), leucine-rich
repeats (LRR), a Ras of complex (Roc), a C-terminal of Roc (COR), kinase domain and WD40
repeats (Fig. 1). Most of the PD mutations are accumulated around the central core of the
protein, one is found in the LRR, two in the Roc domain (with multiple substitutions), one in
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the COR and two in the kinase domain [16, 17]. The multiple disease-linked mutations in
LRRK2 represent a unique opportunity to explore the activation mechanism of the protein and
its miss-regulation in PD. In this chapter we will focus on the effects of LRRK2 on cellular
signalling, the recent progress in elucidating the activation mechanism and discuss possible
ways to therapeutically target LRRK2 mediated PD.
2. Cellular function of LRRK2
Although several potential LRRK2 mediated pathways and interaction partners have been
identified, yet much about the cellular functions of LRRK2 and LRRK2 mediated progression
of PD remains unknown [17]. Below we highlight the evidence for a role of LRRK2 in a wide
variety of these cellular pathways and discuss a possible link to other PD-related genes.
2.1. Neurite development, outgrowth and branching
LRRK2 is directly linked to neurite outgrowth. Several studies have shown that primary
neurons over-expressing mutant LRRK2 have significantly reduced neurite outgrowth and
branching. However, the reported reduction varies and might only be significant in long term
culture [18-20]. Adult neurogenesis and neurite outgrowth is impaired in mice overexpressing
G2019S LRRK2 in the subventricular zone (SVZ) and hipppocampal denate gyrus [21]. This
deficiency of neurite outgrowth can be rescued by inhibiting LRRK2 kinase activity with non-
specific or more specific LRRK2 inhibitors, such as staurosporin [20] or G1023 [22], respec‐
tively. A recent study analysed LRRK2 expression in neonatal and postnatal mouse embryo
and showed that LRRK2 expression can be detected in E10.5 of neural tissue. At the time of
neurogenesis, prominent expression is found in the ventricular and SVZ of the telencephalon
[23]. LRRK2 is also expressed in adult SVZ, where neural stem cells generate neurons in adult
brain [24]. Both R1441G and G2019S LRRK2 impair development of neural stem cells [25-27],
whereas LRRK2 deficient cells have increased neurite development [25, 28, 29]. Although the
Figure 1. Domain topology of human LRRK2. The labels show the segregating mutations of LRRK2 in Parkinson's dis‐
ease (green box), cancer associated mutations (blue box) and Crohn's disease (yellow box).
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mechanisms are yet to be identified, these data show that LRRK2 is regulating neurite-, and
neural development. Interestingly, LRRK2 is not only controlling neurite development via its
kinase activity, also the LRRK2 G-domain and protein-protein interaction domains play a
direct and important role. Tubulin, ArfGAP1, Rac1 and DVL family proteins bind to and/or
are regulated by the G domain of LRRK2 and subsequently modulate the cytoskeleton [30-34].
Wnt signalling is essential for several steps in neural development, including presynaptic
assembly, signal transduction at the postsynaptic cleft and adult neurogenesis [35, 36].
Overexpression of Wnt7a or inhibition of the Wnt signalling suppressor GSK3β promotes
neuron differentiation and maturation [37, 38]. LRRK2 interacts with both the Wnt co-receptor
low-density lipoprotein receptor-related protein 6 (LRP6) and the downstream DVL proteins,
suggesting that LRRK2 might function as a scaffold for Wnt signalling proteins [39].
2.2. Autophagy
It is generally accepted that neurodegenerative diseases are associated with dysregulation of
autophagy [40]. Autophagy is the regulated self-degradation of damaged organelle, ubiquiti‐
nated proteins and protein aggregates by lysosomes. Autophagy is an adaptive response which
is stimulated by stress or unfavourable conditions, such as starvation, accumulation of
aggregate-prone proteins, oxidative stress, and infection [41]. Autophagy is a double-edged
sword; it can promote cell survival or lead to cell death [42]. Autophagy regulates the removal
of protein aggregates, which are a common symptom in neurodegenerative diseases, and
thereby promotes cell survival [43-45]. Protein aggregates such as α-synuclein [46], tau [47],
and huntingtin [48] are cleared by autophagy. Disruption of the autophagy related genes atg5
or atg7 in mice, results in severe impairment autophagy and neurodegeneration [49, 50]. The
purkinje cells of the mutant mice are characterized by axonal dystrophic swelling and
degenerate within a few weeks after birth [51, 52]. Mice with conditional knockdown of atg7
gene in the substantia nigra and cerebellum showed age-related loss of dopaminergic neurons
and autophagy deficiency dependent accumulation of alpha-synuclein aggregates [53].
Expression of LRRK2 G2019S in retinoic acid differentiating SH-SY5Y neuroblastoma cells
results in the accumulation of LRRK2 containing-autophagic vacuoles and shortens neuritic
processes. Cells expressing wild-type LRRK2 show a similar but less severe phenotype.
Disruption of atg7 and microtubule-associated protein 1A/1B-light chain 3 (lc3) in these LRRK2
mutants completely rescues the phenotype [54]. Co-localization of LRRK2 with p62 and LC3
puncta in autophagic vacuoles is reported for human brain and by several other cell culture
studies [55]. Not only overexpression of wildtype and mutant LRRK2 increases accumulation
of autophagic vacuoles and the induction of autophagy [56-58], also knocking down LRRK2
activity by either RNAi or with specific LRRK2 inhibitors stimulates autophagy [59]. In
addition, LRRK2 activity itself is regulated by macroautophagy and chaperon-mediated
autophagy (CMA). LRRK2 inhibits CMA and hinders clearance of α-synuclein by CMA [60].
The complex role of LRRK2 in autophagy is not only playing a role in Parkinson’s disease but
has been linked to several other diseases as well (see below).
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2.3. Mitochondrial disease
Mitochondrial dysfunction in the pathogenesis of PD has been studied extensively. Although
the cellular mechanism remains largely unclear, LRRK2 seems to be important for proper
mitochondrial regulation. Some reports suggest that LRRK2 partly localizes in mitochondria
and several LRRK2 PD associated mutations results in impaired mitochondrial function [61].
Cells carrying the LRRK2 G2019S mutation display a general uncoupling of the oxidative
phosphorylation [62]. The mitochondrial potential and intracellular ATP levels are reduced
along with increased oxygen utilization [62]. Also shape and organization of the mitochondria
are significantly affected as they appear elongated with an enhanced interconnectivity [63].
The increased kinase activity of LRRK2 G2019S leads to an increased AMP- activated protein
kinase (AMPK) level [57]. Since, AMPK is an autophagy regulating protein, its enhanced
activity results in an increased number of autophagosomes [57]. High levels of autophagy/
autophagic vacuoles lead, as described above, to a vulnerability and thus retraction and
degeneration of neurons, one of the main characteristic features of PD [54]. Several other PD
associated proteins, including α-synuclein, Parkin, DJ- 1, PINK1 and HTRA2 [64-66], show
similar defects in mitochondria regulation, suggesting that LRRK2 and other PD associated
proteins share common pathogenic pathways.
2.4. Common pathways for LRRK2 and other PD-relelated proteins?
Lewy bodies are protein aggregates found in degenerating dopaminergic neurons of PD
patients. They are composed of many different proteins, including LRRK2 and α-synuclein
[67, 68]. α-synuclein is a small protein (140 amino acids) that is located in presynaptic nerve
terminal vesicles, plasma membrane lipid rafts and the nucleus [69-71]. Recent studies show
that α-synuclein promotes SNARE-complex assembly [72, 73], and either overexpression or
aggregation of α-synuclein interferes with vesicular trafficking [74-76]. Phosphorylation of α-
synuclein is critical for aggregation and pathology. Since phosphorylation of α-synuclein
serine residue 129 in HEK293T expressing LRRK2 is increased, it was initially proposed that
α-synuclein is a direct substrate of LRRK2 [77]. However, phosphorylation of α-synuclein is
normal in LRRK2-/- mice [78], suggesting that the rather weak effect of LRRK2 on α-synuclein
S129 phosphorylation in cells is most likely indirect. Expression of LRRK2 and α-synuclein is
co-regulated; increase of α-synuclein in mouse striatum results in increased LRRK2 transcrip‐
tion [79]. Both LRRK2 and α-synuclein interact with Rab5, which is important for vesicle
trafficking [80, 81], suggesting LRRK2 and α-synuclein might share common pathways.
Recessive mutations of Parkin, PINK1 and DJ-1 are causative to PD [82]. PTEN-induced kinase
1 (PINK1) is important for mitochondrial function and its deletion leads to increased suscept‐
ibility to oxidative stress [83, 84]. PINK1 is a cytosolic serine/threonine kinase under steady-
state condition and its mitochondrial localization is stabilized by decreased mitochondrial
membrane potential, an indicator of damaged mitochondria [85]. Parkin is an E3 ubiquitin
ligase, which is phosphorylated and recruited to mitochondria by PINK1. The activated Parkin
and PINK1 in conjugation clear damaged mitochondria via selective degradation and autoph‐
agy [85]. Co-expression of Parkin and LRRK2 G2019S in flies protects rotenone-induced
neurodegeneration of dopaminergic neurons [86]. Expression of LRRK2 PD mutants in pink1-
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null flies enhances the phenotype [87]. In human cells, LRRK2 is found to interact with Parkin,
and co-expression of the two proteins increases LRRK2 containing aggregates. Altogether, this
suggests that LRRK2 and PINK1/Parkin pathway are using similar pathways for the regulation
of mitochondrial function. DJ-1 is a redox sensitive protein that is linked to a large variety of
function, for example Ras-dependent cell transformation, neuroprotection, transcription,
apoptosis suppression, P53 signalling, chaperon and protease [88]. It protects neurons from
oxidative stress, by scavenging mitochondrial peroxide through oxidation of cysteine residues,
and by binding metal ions like mercury and copper [89]. In cells that are exposed to oxidizing
agents and mouse brains treated with rotenone, DJ-1 converts to more acidic isoforms [90,
91]. DJ-1 deficient cells, including cell lines and primary neurons, display altered mitochon‐
drial morphology and an increase in autophagic flux [92]. PINK1 and Parkin overexpression
can rescue the mitochondrial morphology of dj-1-null cells, but vice versa DJ-1 cannot rescue
the defects of PINK1 and Parkin mutants. However, DJ-1 can protect PINK1 deficient neurons
from oxidative stress induced by rotenone, suggesting DJ-1 may act both upstream and parallel
to the PINK1/Parkin pathway [93]. In comparison to PINK1/Parkin, LRRK2 shows a less direct
relation with DJ-1, albeit it still clearly exacerbate the eye phenotype of DJ-1 overexpression /
loss in Drosophila [87]. As described previously, LRRK2 is important for autophagy in neurons,
thus it is tempting to speculate that LRRK2 plays a role together with PINK1/Parkin and DJ-1
in regulating mitochondrial homeostasis.
2.5. LRRK2 and other diseases
Mutations in LRRK2 have been linked to several other diseases, including Crohn’s disease and
cancer. Carriers of LRRK2 G2019S mutation have an increased risk of non-skin cancer [94, 95].
Knock-down of LRRK2 in different cancer cell lines by RNAi, results in decreased stability of
the 4E-BP1 protein [96]. Stability of 4E-BP1 protein is dependent on its phosphorylation state;
it is a known downstream target of mTOR, inhibition of mTOR leads to accumulation of
dephosphorylated 4E-BP and blocks cell transformation in a Kaposi’s sarcoma model [97]. The
PI3K/mTOR pathway is very frequently dysregulated in human cancer [98]. Previously, 4E-
BP was identified as a direct LRRK2 kinase substrate (see section 3.3), suggesting LRRK2 might
play a role in regulating 4E-BP stability and thus the oncogenic PI3K/mTOR pathway.
Genome wide association studies linked LRRK2 mutations to Crohn’s disease (CD) and
leprosy [99, 100]. CD associated mutations in the LRRK2 locus are located in non-coding
regions, with an exception of the polymorphism rs3761863, which is leading to M2397T
substitution in the WD40 repeats of LRRK2 [99]. CD is a chronic inflammatory disorder which
primarily affects the gastrointestinal tract. Patients with CD have defective macrophages and
neutrophils, resulting in a deficient innate immunity [101, 102]. LRRK2 is widely expressed in
many organs and tissue, including brain, kidney and spleen. In the spleen, LRRK2 is highly
expressed in CD19+ B cells, whereas lower expression was detected in CD4+ or CD8+ T-cells,
macrophages, and monocytes [103, 104]. In macrophages, LRRK2 expression is induced by
activation of Toll-like receptors and viral transduction [103]. CD patients exhibit high concen‐
trations of proinflammatory cytokines, including interferon-γ (IFN- γ), which induces LRRK2
expression in macrophages [105]. In cell-based reporter studies, LRRK2 is found to activate
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NFκB and inhibit NFAT, which both are important transcription factors in the immune system
[103, 106]. Interestingly this effect is independent of LRRK2 kinase activity, since expression
of both wildtype and kinase dead LRRK2 result in a similar phenotype.
3. Intramolecular LRRK2 activation mechanism
LRRK2 has two bona-fide enzymatic activities from its Roc and kinase domain. It has been
shown that both a functional Roc G-domain and kinase are essential for the pathogenicity of
LRRK2. Importantly, several of the pathogenic mutations in LRRK2 result in decreased GTPase
activity and enhanced kinase activity, suggesting a possible PD-related gain of abnormal
function [107-109]. However the exact molecular mechanisms by which these mutations
enhance LRRK2 catalytic activity are not completely resolved so far. Because of the lack of
sufficient high quality recombinant LRRK2 protein, important understanding of the complex
regulatory mechanism of LRRK2 has come from work with related Roco family proteins.
3.1. Homologous Roco proteins as model to study the mechanism of LRRK2 mediated PD
Roco proteins constitute a novel family of complex Ras-like GTPases that have an unique
domain architecture [15]. Roco proteins are characterized by the presence of a Ras-like Guanine
nucleotide binding domain, called Roc (Ras of complex proteins), followed by a COR domain
(C-terminal of Roc), a conserved stretch of 300-400 amino-acids with no significant homology
to other described protein domains (Fig. 2). The Roc and COR domains always occurs as a pair
and so far no proteins are identified containing either the Roc or COR domain alone, suggesting
that these two domains might function as one inseparable unit. Roco proteins were first
identified in the social amoeba Dictyostelium discoideum and are found in prokaryotes, plants
and metazoa, but not in Plasmodium and yeast. Based on domain topology, the family of Roco
proteins can be divided into three groups, each containing at least one mammalian member.
The first group is found in mammals (MASL1), plants and in prokaryotes. These proteins
contain besides a Roc and COR domain always a N-terminal stretch of leucine-rich repeats
(LRR), which are supposed to be involved in protein-protein interaction. The second group of
Roco proteins is present in Dictyostelium and metazoa. In these proteins the Roc domain is
again preceded by LRRs and the COR domain always succeeded by a kinase domain of the
MAPKKK subfamily of kinases. A subset of Roco proteins contains the metazoan tumour
suppressor death-associated protein kinases (DapK) domain, which is found in many proteins
with apoptotic function [110]. Although there is a high variation in additional regulatory
domains among the Roco proteins, previous studies have shown that the function and
regulation of the catalytic core is conserved.
3.2. Dictyostelium Roco proteins to study the LRRK2 activation mechanism
Dictyostelium discoideum is a social, soil- dwelling amoeba that feeds on bacteria. The organism
is genetically tractable with the ease of making gene disruptions and inducible expression, and
at the same time it can be grown to large quantities for biochemical analyses [111]. Most
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Figure 2. Domain architecture of the Roco family of proteins. The domains are leucine-rich repeat (LRR), Ras in com‐
plex domain (Roc), C-terminal of Roc domain (COR), ankyrin repeat (ANK), Kinase domain (Kinase), WD40 repeats
(WD), armadillo repeat (ARM), Rho guanine nucleotide exchange factor domain (RhoGEF), Pleckstrin domain (PH),
Dishevelled, Egl-10 and Pleckstrin domain (DEP), Rho GTPase activating protein domain (RhoGAP), Kelch motif (K),
regulator of G protein signalling domain (RGS), N-terminal motif of RasGEF (N-GEF), Ras guanine nucleotide exchange
factor domain (RasGEF), cyclic nucleotide binding domain (cNB), glucosyltransferases, Rab-like GTPase activators and
myotubularins domain (GRAM), N-terminal myotubulin-related domain (myotub), protein tyrosine phosphatase do‐
main (PTP) and death domain (DD).
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importantly, many key pathways are conserved between Dictyostelium and human. Therefore,
Dictyostelium offers unique advantages for studying fundamental cellular processes, as well
as the molecular causes of human diseases [112]. Although Dictyostelium neither has a brain
nor muscle, it is, as described below, an excellent model to study the molecular basis of LRRK2-
mediated PD.
Dictyostelium contains eleven Roco family members, that all belong to the second subgroup of
the Roco family. They are sharing the characteristic Roc, COR and kinase domains and in
addition most also have LRR (Fig. 2, [15]). Dictyostelium Roco proteins are structurally more
varied than the Roco proteins found in all the other species together; various domains are
additionally fused to the conserved region. Roco proteins are most likely the result of recent
gene duplications, and are very homologous to mammalian LRRK2 [113]. Disruption of
Dictyostelium Roco genes leads to very different phenotypes, indicating that they are involved
in multiple cellular processes. They participate in processes as diverse as chemotaxis, cell
division, osmotic-stress-response and development [114]. The strong and diverse phenotypes
of the Dictyostelium Roco disruption mutants therefore provide a strong tool to investigate the
activation mechanisms of Roco proteins. Especially the studies with Dictyostelium Roco4 gave
mechanistic insight into the regulation of LRRK2 [114, 115]. Dictyostelium Roco4 has the same
domain architecture as LRRK2, but in contrast to LRRK2, Roco4 is biochemically and struc‐
turally more tractable [115]. Roco4 plays an important role in the late development stage of
Dictyostelium [114]. During the vegetative growth stage, single Dictyostelium cells feed on
bacteria and divide by simple mitotic divisions. In times of starvation, a developmental
program is initiated, which is accompanied by major changes in gene expression. As a result,
single cells are able to form aggregates via cAMP- dependent chemotaxis, resulting in the
development of mobile multicellular forms, called slugs [111]. Eventually, the slugs will
permanently settle down, culminate and generate fruiting bodies, which consist of a cellulose
containing stalk and basal disc and end in a spore head [116]. Single cell amoebae are embed‐
ded in the spore head, which are resistant to extreme temperatures or drought and can be
Figure 3. LRRK2 function and inhibition experiment with Dictyostelium cells. Wild-type, roco4-null and roco4-null cells
expressing Roco4-LRRK2 kinase in which the kinase domain of Roco4 has been replaced with the kinase domain of
LRRK2, were allowed to develop for 48 hours on nutrient-free agar. Pieces of agar were excised and photographed
from the side. roco4-null cells fail to make a normal fruiting body due to defective synthesis of cellulose. The right pan‐
el shows a side view of the development of wild-type cells in the presence of the LRRK2-inhibitor H1152. Cells in the
presence of 0.5 mM H1152 have the typical roco4-null phenotype. Figure modified with permission from Proc. Natl.
Acad. Sci. USA, (Gilsbach et al., 2012).
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released upon germination under more favourable environmental conditions [111]. Cells
lacking roco4 undergo the characteristic streaming, aggregating and mound forming phases,
however after 12 hours of starvation the cells start to display severe developmental defects.
The formation of slugs and subsequent stalks and spore heads is severely delayed; 72 hours
in the mutant cells, compared to 24 hours in wild-type [114]. Furthermore, roco4-null cells
display aberrant fruiting body morphology as the spore heads are located on the agar surface
due to a reduced cellulose level and thus instable stalks (Fig. 3, second panel). The strong
developmental phenotype of roco4-null cells was used to determine essential structural
elements in the protein. Remarkably, this phenotype can completely be rescued by expression
of a chimeric Roco4 protein, in which its kinase domain has been replaced with the LRRK2
domain (Fig. 3, third panel) [115]. Furthermore, Roco4 kinase activity is inhibited by LRRK2
inhibitors (Fig. 3, right panel), and LRRK2 phosphorylates specific developed artificial
substrates for LRRK2 in vitro [115, 117]. This shows that Roco4 has properties very much
resembling those described for LRRK2, indicating that Roco4 protein thus can serve as a valid
model to understand the complex structure and regulatory mechanism of LRRK2.
3.3. LRRK2 kinase activity
Protein kinases catalyze the transfer of γ-phosphate of ATP to the hydroxyl group of serine/
threonine/tyrosine in peptide substrates. Due to the simplicity, stability, and reversibility,
protein phosphorylation is chosen by nature for modulating protein functions. Phosphoryla‐
tion allows specific and dedicated control over enzymatic activities, regulation of protein
localization and the transition between the ordered and disordered states of proteins [118].
Therefore, protein kinases are essential for many biological processes such as energy metab‐
olism, cell cycle progression, transcription and cytoskeleton rearrangement. There are more
than 500 protein kinases identified in the human genome, of which the majority are serine/
threonine kinases, a much smaller amount is tyrosine specific and a trace amount are atypical
kinases [119].
LRRK2 kinase activity is extensively studied since its discovery, and it is found to be essential
for neuronal toxicity induced by PD mutant of LRRK2 [120, 121]. LRRK2 and Roco proteins
are serine/threonine specific kinases. Previously the structures of Roco4 kinase wild-type and
the PD-related mutants G1179S and L1180T (G2019S and I2020T in LRRK2) were solved [115].
Like almost all kinases, Roco4 consists of a canonical, two-lobed kinase structure, with an
adenine nucleotide located in the conventional nucleotide binding site [118, 122]. The N-
terminal lobe is smaller, which is composed of an anti-parallel β-sheet and the large conserved
αC-helix. It is followed by a linker connecting the larger C-terminal lobe, which is composed
predominantly of α-helices and is containing the activation loop with the conserved DFG motif
at the N-terminus [115]. The ATP binding pocket is located between the N- and C-terminal
lobes and forms together with the activation segment and αC-helix the catalytic site of the
kinase. In its inactive (dephosphorylated) form, the activation segment of Roco4 is disordered,
and not visible in the crystal structure. In the active (phosphorylated) conformation, the αC-
helix is ordered and packs against the N-terminal lobe. This conformational change between
the active and inactive conformation is conserved between most kinases, and often dependent
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on autophosphorylation of the activation loop [118, 122-124]. In vitro kinase and in vivo rescue
experiments showed that Roco4 S1187 and S1189 are essential for regulating Roco4 kinase
activity. Autophosphorylation is well demonstrated in LRRK2 by numerous studies. LRRK2
contains with T2031/S2032/T2035 three potential phosphorylation sites in the activation loop.
Studies using phosphospecific antibodies have shown that all three sites are phosphorylated,
but like for Roco4, only the two later sites, S2032 and T2035, are important for LRRK2 activity
in vivo [125]. Most other autophosphorylation sites are located in the Roc domain and kinase
domain, such as S1292, T1348, T1349, T1357, T1503, T1967, T1969 [22, 126, 127]. Mutations of
these residues significantly affect the enzymatic activities of LRRK2. Importantly, mutating
S1292 to alanine [22] or inhibiting kinase activity with inhibitors, completely rescues neurite
outgrowth in LRRK2 PD mutants. This suggests that LRRK2 kinase activity is important for
both the intramolecular activation mechanism, as well, for downstream signalling. Several
putative LRRK2 kinase substrates have been identified so far. LRRK2 phosphorylates 4E-BP
[128] and FoxO and thereby modulates their translation and transcription activities. However,
the relevance of 4E-BP phosphorylation by LRRK2 for the progression in PD is still under
debate [129-131]. Phosphorylation of FoxO induces expression of the pro-apoptotic Bcl-2
protein, Bim, and the endogenous caspase-8 inhibitor, c-FLIP, leading to programmed cell
death [132-134]. Therefore, FoxO may be one of the missing links between LRRK2 and cell
death in neurons. [135]. Several LRRK2 substrates are linked to cytoskeleton remodelling;
moesin promotes actin rearrangement in neurons [136, 137], and β-tubulin and tubulin-
associated tau are important for neurite outgrowth and axonal transport [138-140].
3.4. Mechanism of increased kinase activity in LRRK2 PD mutants
The most prevalent PD mutation in the kinase domain is G2019S, which enhances kinase
activity, while the PD-related mutation I2020T shows a slightly decreased activity [108, 109,
117, 121, 141]. Recently the molecular mechanism by which the G2019S mutation enhan‐
ces LRRK2 was resolved using Dictyostelium Roco4. The LRRK2 G2019 and I2020 residues
are  conserved in  Dictyostelium  Roco4 and correspond to  G1179 and L1180,  respectively.
Overlay of the solved Roco4 wild-type and the Roco4 G1179S structure didn’t show large
differences in the overall structure, however closer observation revealed that S1179 makes
a new hydrogen bond with R1077, thereby presumably stabilizing the activation loop and
the αC-helix in their active conformation. R1077 is conserved in almost all Roco proteins
and corresponds  to  LRRK2 R1918.  Kinase  activity  measurement  with  the  Roco4  double
mutant  G1179S/R1077A and the  homologous  LRRK2 double  mutant  G2019S/R1918A,  in
which the new hydrogen bond is no longer possible, confirmed the proposed mechanism
since it shows wild type kinase activity [115].
The structure of the PD-related mutant L1180T showed that the T1180 side-chain points into
the solvent and revealed that it is most likely not directly involved in regulating kinase activity.
Importantly, the data show that the PD-related effect of LRRK2 mutations result from different
defects in the LRRK2 activation mechanism and suggest that different LRRK2 mutations such
as S2019 and T2020 might require different ways of inhibition for the purpose of drug
development [115, 142].
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3.5. The RocCOR tandem
The Roc domain of LRRK2 belongs to the family of small G-proteins. G-proteins are GTP binding
proteins which switch between an active GTP- and inactive GDP-bound state. The G-domain
has an universal switch mechanism that carries out the basic function of nucleotide binding and
hydrolysis [143]. The universal switch mechanism between the inactive GDP and active GTP
form often consist of only small structural changes in the so called switch regions [144]. Although,
the two nucleotide-bound states have only a slightly different conformation, only the GTP-
bound conformation possesses high affinity for effector proteins [145]. In Roco family mem‐
bers the G-domain always occurs in tandem with the COR domain. Studies with both LRRK2
and Dictyostelium Roco4 revealed that a functional Roc domain is essential for kinase activity,
the COR domain functions as the dimerization device and disruption of Roc or the kinase domain
by a single point mutation leads to the complete inactivation of the protein. These suggest that
the Roc-COR tandem is regulating kinase activity and/or that the kinase is regulating the activity
of  Roc  by autophosphorylation [146].  The cycle  of  “classical”  small  G-protein  is  strictly
controlled by GEFs (Guanine nucleotide Exchange Factors), which catalyze the exchange from
GDP to GTP, and the intrinsic low GTP hydrolysis rate is increased by GAPs (GTPase Activat‐
ing Proteins) [147]. It is well established that LRRK2 and other Roco proteins are active as a
dimer ([148-150], see also below). The previously solved structure of the Roco protein from the
bacteria Chlorobium tepidum,  revealed that COR is the dimerization device and that Roco
proteins, including LRRK2, belong to the GAD class of molecular switches (G proteins activated
by nucleotide dependent dimerization) [149, 151]. This class also includes proteins such as signal
recognition particle, dynamin and septins [151]. It is proposed that the juxtaposition of the G
domains of two monomers in the complex across the GTP-binding sites activates the GTPase
reaction and thereby regulates the biological function of these proteins (Fig. 4). Since GTPase
activity is regulated within the dimer complex, GTP hydrolysis by Roco proteins is not regulated
by GAP’s. LRRK2 and Roco proteins have a much lower affinity (μM range) compared to other
small G-proteins (nM range), and therefore most likely do not need GEFs for activation [149,
152]. The PD-related mutations, R1441C/G/H in the Roc domain and Y1699C in the COR domain,
do not affect nucleotide binding, but significantly decrease GTPase activity [153, 154]. Impor‐
tantly, the structure of the Chlorobium tepidum Roco protein showed that the PD-analogous
mutations of the Roc and COR domain are in close proximity to each other at the dimer interface.
Furthermore, these mutations are present in a region of the protein that is strongly conserved
between bacteria, Dictyostelium and man. PD-mutations in the Chlorobium tepidum protein, like
that of LRRK2, decrease the GTPase reaction, most likely due to altered interaction in the dimer
between the Roc and COR domains [149].
3.6. Function of the N-terminus of LRRK2
The N- terminal part of LRRK2 consists of Armadillo repeats (ARM), Ankyrin repeats (ANK),
and leucine-rich repeats (LRR) (Fig. 1). All these domains are commonly found in signalling
proteins, in which they have a role in protein-protein interaction or assembly of large protein
complexes [155]. The N-terminal segment of LRRK2 is most likely involved in regulating
activity and/or localization. ARM are approximately 40 amino acid long tandem repeated
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sequences that form superhelix of helices. ANK consist of seven structural repeats, each repeat
forms two anti-parallel helices ending with a loop or hairpin [156, 157]. LRR are defined by an
11 amino acid long consensus sequence LxxLxLxxNxL, where leucine can be replaced by
isoleucine, valine or phenylalanine [155]. The LRRK2 LRR domain is composed of 13 repeats,
allowing the formation of its characteristic horseshoe shaped structure due to parallel lining
β- sheets with ending α- helices [139, 158, 159]. The LRR domain of LRRK2, and Dictyosteli‐
um Roco4, are not involved in Roc or kinase activation in vitro, but are absolutely essential for
activity of the protein in vivo [160, 161]. Recent data suggest that the LRR are directly involved
in determining input/output specificity of the Roco proteins, most likely by binding upstream
proteins that activate specifically the Roco protein and/or by selectively binding of the
substrate (AK unpublished data). Previously, it has been shown that 14-3-3 proteins bind to
the N-terminus of LRRK2 [25]. 14-3-3 are highly conserved proteins that have been found in a
variety of organisms, including mammals, plants, yeast, Drosophila, and Dictyostelium [162,
163]. In human, the 14-3-3 protein family consists of 7 structural similar yet distinct isoforms:
α, β, γ, δ, ε, ζ, η [162]. The proteins exist as homo- or functional active heterodimers and are
important for various signalling pathways, including neurotransmitter synthesis in mamma‐
lian brain tissue, via direct ligand binding [163, 164]. Interaction of 14-3-3 with LRRK2 is
dependent on the phosphorylation of two conserved serine residues (S910, S935), situated at
the N- terminal part of LRRK2 anterior to the LRR domain [158]. Since several LRRK2 specific
kinase inhibitors abolish 14-3-3 binding, it is proposed that the binding is regulated by auto-
phosphorylation [165, 166]. However, other studies suggest that LRRK2 interaction is depend‐
ent on a so far unidentified upstream kinase [167]. Disrupted phosphorylation of the serine
residues results in strong defects in LRRK2 signalling; the protein is delocalized and accumu‐
lates in inclusion like bodies instead of being transported to the cell membrane [158, 166].
Interestingly, pathogenic PD mutants of LRRK2 display a similar dysfunctional phenotype,
suggesting a direct link between LRRK2 and 14-3-3 signalling.
3.7. WD40 domain at the C-Terminus of LRRK2
LRRK2 contains a C-terminal WD40 domain. It comprises seven repeats each of which consists
of antiparallel, four stranded β- sheets resulting in a circular propeller-like structure. WD40
repeats have a high positive net charge and several hydrophilic surfaces, and are therefore
often involved in membrane binding and interaction with negatively charged proteins [157].
Two non-conserved mutations which are suggested to be involved in the onset of PD are found
in the WD40 domain of LRRK2: G2385R and T2356I [157]. A yeast-two hybrid screen showed
a direct interaction of WD40 repeats with the Roc domain [168]. In addition, LRRK2 lacking
the WD40 domain has abolished abilities to form dimers, displays impaired activity and
localization [169]. Together these results suggest an important role for the WD40 domain in
the intramolecular regulation of LRRK2 activity.
3.8. LRRK2/Roco activation model
We have translated all biochemical, genetic and structural data into a model for the regulatory
mechanism of LRRK2 (Fig. 4). LRRK2 is monomeric and inactive in the cytosol, but attains pre-
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Figure 4. Proposed model for the function and activation mechanism of LRRK2.
The Potential of Targeting LRRK2 in Parkinson’s Disease
http://dx.doi.org/10.5772/57362
173
dominantly dimeric and in the active state at the membrane [150]. These results suggest that
LRRK2 cycles between a low activity monomeric state and high activity dimeric state. The
previously solved structure of the Roco protein from Chlorobium tepidum revealed that COR is
the dimerization device and that Roco proteins belong to the GAD class of molecular switches.
In the GDP-bound inactive state the G-domains are flexible, but in the active form the G-
domains come in close proximity to each other. This conformational change is transmitted to
the kinase domains to allow the activation loops of the two kinase protomers to be autophos‐
phorylated and activated. The GTPase reaction is also dependent on dimerization, because
efficient catalytic machinery is formed by complementation of the active site of one protomer
with that of the other protomer. In this way the GTPase reaction functions as a timing device
for the activation of the kinase and the biological function of the protein. Consistently, PD-
related mutations have reduced GTPase activity and enhanced kinase activity (MS in prepa‐
ration, [16]). The N- and C- terminal segments are not important for kinase activity in vitro, but
appear to be essential in vivo [114, 160, 161] and most likely determine the input and/or output
specificity of the proteins. One of these upstream regulators might be 14-3-3, which binds in a
phosphorylation dependent way to the N-terminal segment of LRRK2, thereby regulating its
subcellular localization and secretion in exosomes [158, 170, 171].
4. Therapeutic targeting LRRK2
The multiple allosteric and enzymatic functions within one protein make LRRK2 an excellent
therapeutic target (Fig. 5). Below we highlight the recent progress in identifying LRRK2 kinase
inhibitors and discuss alternative ways of targeting LRRK2-mediated PD-disease.
Figure 5. Strategies of LRRK2 inhibition.
4.1. LRRK2 kinase as a therapeutic target
Kinases are one of the most potent classes of drug targets and have been effectively used in
the treatment of cancer, immunological, neurological and infectious diseases [172]. The
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majority of inhibitors directly target the ATP binding site. They are divided into three groups;
most of the inhibitors reported are type I inhibitors, which target the active conformation and
directly compete with ATP for the binding pocket. Type II inhibitors also bind in the ATP
binding pocket resulting in a change from the active DFG-in into an inactive DFG-out confor‐
mation. Type III inhibitors directly target the DFG – out conformation. One of the approved
kinase inhibitors for renal cell carcinoma treatment is Sunitinib (Sutent(®), Pfizer Inc.). It is a
tyrosine kinase inhibitor which has several targets and inhibits tumor cell proliferation, and
angiogenesis [173]. LRRK2 kinase activity is critically linked to clinical effects, and the most
prevalent PD mutation, LRRK2 G2019S in the kinase domain, enhances kinase activity by 2-4
folds [108, 141]. Therefore LRRK2 kinase inhibitors are an intensively pursued class of drug
targets. Several non selective inhibitors were found to inhibit LRRK2 with their IC50 values in
nanomolar range, including staurosporin, K252A and Su-11248 (Sunitinib) [141, 174]. Several
ROCK inhibitors have also been found to inhibit LRRK2 with similar efficiencies (low micro‐
molar range), such as isoquinolinesulfonamides hydroxyfasudil and H1152, and the structur‐
ally unrelated Y-27632. Noteworthy, not all ROCK inhibitors inhibit LRRK2;
isoquinolinesulfonamides do not inhibit LRRK2 as effective as ROCK and the aminofurazan
ROCK inhibitor GSK269962A cannot inhibit LRRK2 [175]. Despite a high degree of conserva‐
tion in the ATP binding site of kinases, it is possible to develop highly selective kinase inhibitors
[172]. LRRK2-IN-1 is the first one discovered by compound-centric high throughput library
screening [165]. It inhibits both wild-type (IC50 = 13 nM) and G2019S mutant (IC50 = 6 nM) of
LRRK2, and shows high selectivity. Among a panel of 442 kinases, only 12 kinases were
inhibited, with up to 10 μM of LRRK2-IN-1. LRRK2-IN-1 also inhibits LRRK2 activity in human
cells, however dephosphorylation of LRRK2 can only be observed in the kidney and not in the
brain of the mice received intraperitoneal injection of the inhibitor, suggesting that this potent
and selective LRRK2 inhibitor is incapable of crossing the blood brain barrier [165].
The recently identified LRRK2 inhibitors, HG-10-102-01 [176] and GNE-7915 [177] are selective
and brain penetrant [178]. However, long-term inhibition of LRRK2 with these inhibitors leads,
similar to disrupting LRRK2 in mice, to kidney abnormality [179-181]. Developing kinase
inhibitors specific to PD mutants of LRRK2, not affecting wild-type, might therefore be the
most promising approach. The previous solved structure of the Roco4 kinase PD mutant and
Roco4 kinase in complex with the LRRK2 inhibitor H1152 might be instrumental in this process
[115]. Although current available LRRK2 kinase inhibitor can not be used for PD treatment yet
[178], they provide an excellent tool to study PD in vitro and in vivo and form a good starting
point to develop better PD drugs.
4.2. Alternative therapeutic approaches
Although most attention has concentrated on targeting LRRK2 kinase activity so far, only for
the G2019S consistently an increased kinase activity has been reported. All other pathogenic
mutations show inconsistent-, modest- or no effect on kinase activity. This suggests that
different PD mutations in LRRK2 have a different defect in the activation mechanism and
might require different ways of inhibition for the purpose of drug development (Fig. 5). The
LRRK2 mutations in the Roc (R1441C/G/H), and COR (Y1699C) domain have a decreased
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GTPase activity [153, 154], suggesting GTPase activity forms a good therapeutic target. Since
Ras is the most common oncogene in human cancer, many studies have focussed on identifying
Ras inhibitors. Targeting the G-domain could be done by using small compounds that bind to
the nucleotide binding site and resemble the GDP bound off state or increase the GTPase
reaction. Due to the high nucleotide affinity and the high cytosolic concentration, it has been
very challenging to identify a therapeutic target of Ras. However, since LRRK2 has a much
lower nucleotide affinity and the GTPase activity is regulated by dimerization, the LRRK2 G-
domain may provide a better therapeutic target.
The N- and C-terminal segments of LRRK2 contain several protein-protein interaction
domains which are involved in regulating kinase activity, oligomerization, and/or localization
(Fig 5). As described above, LRRK2 cycles between a low active monomeric cytosolic state and
high active dimeric membrane bound state. The regulation of LRRK2 membrane association
is not well understood, but probably includes dimerization, post-translational modification
and protein-protein interactions [158, 170, 182]. 14-3-3 proteins bind in a phosphorylation
dependent manner to the N-terminus of LRRK2, which is important for LRRK2 localization
and activity [25]. All purified or co-immunoprecipitated LRRK2 fragments are dimeric [148],
and LRRK2 kinase activity seems to be dependent on dimerization [150, 170]. Active LRRK2
is a constitutive dimer by high affinity interaction of the COR domains, suggesting that in the
cytosol the dimerization is most likely covered by regulatory proteins. Importantly, since
LRRK2 activation is dependent on membrane localization and dimerization, inhibiting either
of these properties may be a good therapeutic approach.
5. Conclusion
The multiple disease-linked mutations and enzyme functions within one protein make LRRK2
an excellent therapeutic target. Since several PD mutants result in an increase in LRRK2 kinase
activity, the focus so far has been to develop kinase domain inhibitors as potential PD
therapeutics. However, alternative approaches that target other domains of LRRK2, localiza‐
tion, dimerization, or allosteric modulation of the kinase domain may have significantly
improved therapeutic benefits. To explore these potential therapeutic approaches, it will be
essential to completely understand the molecular activation mechanism, identify upstream
and downstream regulators, and characterize the cellular function of LRRK2. Work with model
organism and biochemical and structural characterization of related Roco proteins from lower
organisms might be important in this enterprise.
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